| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/16/2002 | EP1171115A1 Methods of delivery of cetyl myristoleate |
| 01/16/2002 | EP1171114A1 Method for the treatment of incontinence |
| 01/16/2002 | EP1171113A1 Compounds useful as phosphotyrosine mimics |
| 01/16/2002 | EP1171112A2 Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients |
| 01/16/2002 | EP1171111A2 Granulate with high content of l-carnitine or an alkanoyl l-carnitine |
| 01/16/2002 | EP1171110A2 Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis |
| 01/16/2002 | EP1171109A1 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 01/16/2002 | EP1171108A1 Combination preparation for treating malaria |
| 01/16/2002 | EP1171107A1 Pharmaceutical composition effective against pathological conditions caused by bacteria, viruses, fungi, yeasts and protozoa |
| 01/16/2002 | EP1171106A1 Treatment of certain cancers associated with weight gain |
| 01/16/2002 | EP1171105A1 Transdermal therapeutic system with a highly effective neuroleptic agent |
| 01/16/2002 | EP1171104A2 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 01/16/2002 | EP1171101A1 Method for producing a water-insoluble amorphous or partially amorphous controlled release matrix |
| 01/16/2002 | EP1171100A1 Solubilized pharmaceutical composition for parenteral administration |
| 01/16/2002 | EP1171099A1 Composition containing opioid antagonists and spray dispenser |
| 01/16/2002 | EP1171098A1 A method for improving the half-life of soluble viral-specific ligands on mucosal membranes |
| 01/16/2002 | EP1171097A1 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate |
| 01/16/2002 | EP1171093A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171091A1 Pharmaceutical or cosmetic compositions for the local, intradermal application of hormones |
| 01/16/2002 | EP1171090A2 Methods for regulating the condition of mammalian keratinous tissue |
| 01/16/2002 | EP1171089A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171083A2 Treating hair by targeting enzymes |
| 01/16/2002 | EP1171081A2 Skin care compositions containing combination of skin care actives |
| 01/16/2002 | EP1171078A2 Compositions and methods for effecting the levels of high density lipoprotein (hdl) cholesterol and apolipoprotein ai, very low density lipoprotein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol |
| 01/16/2002 | EP1171003A1 Complete feed for fish larvae and method for preparing same |
| 01/16/2002 | EP1170993A1 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding 4e-bp1 |
| 01/16/2002 | EP1121926A9 Cosmetic preparations containing Waltheria indica extracts |
| 01/16/2002 | EP1087801B1 Topoisomerase inhibitors for prevention of restenosis |
| 01/16/2002 | EP1082012A4 Novel nucleosides having bicyclic sugar moiety |
| 01/16/2002 | EP1024793B1 Osmotic medicament releasing system |
| 01/16/2002 | EP1007067B1 Pharmaceutical compositions containing parthenium integrifolium or parts thereof or an extract or component thereof, the use of such plant material for preparing certain medicines, and a method of preparing an extract of parthenium integrifolium |
| 01/16/2002 | EP1006984A4 Monohydric alcohol derived urethanes and their use in cosmetic formulations |
| 01/16/2002 | EP0981529B1 A new process for the preparation of a pharmacologically active substance |
| 01/16/2002 | EP0969811B1 Mixtures of alkylphosphoric acid esters and their use as cosmetic and pharmaceutical emulsifiers |
| 01/16/2002 | EP0914097B1 Composition and dosage form comprising opioid antagonist |
| 01/16/2002 | EP0886515B1 Use of n-aryl-2-hydroxyalkylamides for stimulating or inducing hair growth and/or arresting hair loss |
| 01/16/2002 | EP0883619B1 Morphine and diamorphine salts of anionic non-narcotic analgesics of the substituted carboxylic acid type |
| 01/16/2002 | EP0880517B1 Quinazoline compounds |
| 01/16/2002 | EP0871732A4 Method of treating sepsis |
| 01/16/2002 | EP0866701B1 Synergistic immunosuppressant composition containing a 2,2'-bi-1h-pyrrole compound |
| 01/16/2002 | EP0865285B1 Compositions, containing bismuth, for the prevention and treatment of gastrointestinal disorders |
| 01/16/2002 | EP0862653B1 NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION |
| 01/16/2002 | EP0859626B1 Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing the said preparation |
| 01/16/2002 | EP0854879B1 Novel 5-o-deosaminyl 6-o-methyl erythronolide a derivatives, preparation method therefor and use thereof for preparing biologically active materials |
| 01/16/2002 | EP0832073B1 Quinazolines and pharmaceutical compositions |
| 01/16/2002 | EP0830132B1 Pharmaceutical composition containing tiagabine hydrochloride and the process for its preparation |
| 01/16/2002 | EP0817645B1 Use of gonadotropin in the treatment of benign prostatic hypertrophy |
| 01/16/2002 | EP0789700B1 Improved process for making a d-(+)-biotine intermediate product |
| 01/16/2002 | EP0782580A4 Parallel selex |
| 01/16/2002 | EP0755254A4 Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists |
| 01/16/2002 | EP0680964B1 PYRROLO [3,2-e]INDOLE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE |
| 01/16/2002 | EP0672180B1 Oligonucleotide modulation of protein kinase c |
| 01/16/2002 | EP0666739B1 An intravenous solution that diminishes body protein and water loss |
| 01/16/2002 | EP0638075B1 Thiazole or imidazole derivatives as maillard reaction inhibitors |
| 01/16/2002 | CN1331797A High energy phototherapeutic agents |
| 01/16/2002 | CN1331748A Method of recombination and agents useful for same |
| 01/16/2002 | CN1331703A Substance for reduction of cholesterol as well as lipids content |
| 01/16/2002 | CN1331698A Brain cell or nerve cell-protective agents comprising ginsenoside Rb1 |
| 01/16/2002 | CN1331697A Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same |
| 01/16/2002 | CN1331695A Organo-phosphorus compounds and their utilization |
| 01/16/2002 | CN1331694A Antihistaminic spiro compounds |
| 01/16/2002 | CN1331693A 1,2-annelated quinoline derivatives |
| 01/16/2002 | CN1331692A Benzisozazoles and phenones as alpha antagonist |
| 01/16/2002 | CN1331691A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331690A 4-(caminomethyl)-piperidine benzamides for treating gastrointestinal disorders |
| 01/16/2002 | CN1331689A 4-and 5-alkynyloxindoles and 4-and 5-alkenyloxindoles |
| 01/16/2002 | CN1331687A Method of preparing delta-9-tetrahydrocannabinol esters |
| 01/16/2002 | CN1331685A Method for preph. of citalopram |
| 01/16/2002 | CN1331684A Sulphoneylxazolamines as therapeutic active ingredients |
| 01/16/2002 | CN1331683A 2-phenylbenzimidazoles and 2-phenylindoles, and prodn. and use thereof |
| 01/16/2002 | CN1331682A Substituted 2-phenylbenzimidazoles, prodn. thereof and their use |
| 01/16/2002 | CN1331680A N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors |
| 01/16/2002 | CN1331679A 3-azabicyclo [3.1.0] hexane derivatives as opiate receptors ligands |
| 01/16/2002 | CN1331677A Pyrrolidine derivatives-CCR-3 receptor antagonists |
| 01/16/2002 | CN1331674A Sulfonamide hydroxamates |
| 01/16/2002 | CN1331606A Oil-in-water emulsion exhibiting protective action against damages to human organs resulting from peroxidation and prodn. and use thereof |
| 01/16/2002 | CN1331601A Antiprotozoal saponins |
| 01/16/2002 | CN1331599A Compounds and their therapeutic use with diabetic complications |
| 01/16/2002 | CN1331598A Medicinal compsns. for treating osseous lesion in multiple myeloma |
| 01/16/2002 | CN1331597A Use of bisphosphonates for prevention and treatment of infectious processes |
| 01/16/2002 | CN1331596A Controlled release galantamine composition |
| 01/16/2002 | CN1331595A Triazine compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 01/16/2002 | CN1331594A Triazineone compounds for treating diseases due to sarcosystis, neospora and toxoplasma |
| 01/16/2002 | CN1331593A Pharmaceutical compsns. contg. tetrahydroisoquinoline compounds |
| 01/16/2002 | CN1331592A Liposomic niflumic acid-new transdermal anti-inflammatory medicine |
| 01/16/2002 | CN1331591A Piperidines as CCR5 modulators |
| 01/16/2002 | CN1331590A Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating disease associated with increase of AT-1 or AT-2 receptors |
| 01/16/2002 | CN1331589A Oral creating supplementation for treating or preventing muscle disuse syndrome |
| 01/16/2002 | CN1331588A Use of 5HT2A and 5HT 2A-2C receptor antagonist for preparing medicines for treating snoring and high resistance syndrome of upper anatomical airways |
| 01/16/2002 | CN1331586A Transparent transdermal nicotine delivery devices |
| 01/16/2002 | CN1331584A Method for preparing effervescent granulate comprising iron gluconate granulate thus obtained and tablets containing same |
| 01/16/2002 | CN1331582A Propofol compsn. comprising gentetate |
| 01/16/2002 | CN1331576A Methods and transdermal compsns. for pain relief |
| 01/16/2002 | CN1331575A Methods and appts. for improved administration of fentanyl and supentanil |
| 01/16/2002 | CN1331561A Novel compsns. and methods for prevention and treatment of protozoal disease |
| 01/16/2002 | CN1331076A Condensed pyrazole compound, composition containing it and its application |
| 01/16/2002 | CN1330936A Medicine prescription of treating burn |
| 01/16/2002 | CN1330923A Medicine for treating foot ringwoorm |
| 01/16/2002 | CN1330922A Medicinal composition for treating or preventing diseases associated with immunodeficiency virus and reverse transcription virus |
| 01/16/2002 | CN1330920A Process for preparing granular ibuprofen |